Tirzepatide

A first-in-class dual GIP and GLP-1 receptor agonist that has demonstrated superior weight loss compared to other incretin-based therapies. Tirzepatide uniquely targets both incretin pathways, producing remarkable results in clinical trials for obesity and type 2 diabetes.

• Dual agonism of GIP and GLP-1 receptors for synergistic metabolic effects
• Enhances glucose-dependent insulin secretion via both incretin pathways
• Slows gastric emptying and reduces appetite centrally
• Improves beta-cell function and insulin sensitivity in adipose tissue

• Personal or family history of medullary thyroid carcinoma
• Multiple endocrine neoplasia syndrome type 2
• History of severe pancreatitis
• Severe renal impairment

Store unused pens at 2–8°C (36–46°F). In-use pens can be kept at room temperature (up to 30°C (86°F)) for up to 21 days.

The SURMOUNT-1 trial showed tirzepatide 15 mg produced an average weight loss of 22.5% over 72 weeks in participants with obesity, with over one-third of participants achieving ≥25% weight loss. SURPASS trials demonstrated HbA1c reductions of up to 2.6% in type 2 diabetes. FDA-approved for both type 2 diabetes (Mounjaro) and chronic weight management (Zepbound).